medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2010, Número 1

<< Anterior Siguiente >>

Acta Pediatr Mex 2010; 31 (1)


Síndrome de opsoclonos mioclonos causado por un neuroblastoma. Informe de un caso

Dávila-Gutiérrez G, Palacios-Acosta JM, Guzmán-Martínez A, Rodríguez-Abarca F, Shalkow- Klincovstein J, Carrasco-Daza D

Idioma: Español
Referencias bibliográficas: 50
Paginas: 36-41
Archivo PDF: 452.72 Kb.


RESUMEN

Informamos el caso de una lactante mexicana con integridad neurológica previa, que desarrolló un síndrome de opsoclonos mioclonos (SOM), sin que tuviera algún proceso infeccioso intercurrente. Tuvo pobre respuesta al tratamiento con prednisona; mejoró parcialmente con inmunoglobulina intravenosa. Un gammagrama con metayodo bencilguanidina mostró la presencia de tejido cromafín a nivel abdominal. Una tomografía computada de abdomen reveló un tumor abdominal. Los estudios de histopatología y extensión permitieron diagnosticar un neuroblastoma diferenciado en estadio 1. Se resecó el tumor y el paciente tuvo una evolución favorable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kaplan M, Salet J, Pean G, et al. Sur une variété d’ataxie cérébelleuse acquise de l’enfance avec tremblement oculaire. Arch Fr Pédiatr. 1959;16: 1124-9.

  2. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry. 1962;25: 271-9.

  3. Brandt S, Carlsen N, Glenting P, Helweg-Larsen J. Encephalopathia myoclonica infantilis (Kinsbourne) and neuroblastoma in children. A report of three cases. Develop Med Child Neurol. 1974;16:286-94.

  4. Talon P, Stoll C. Syndrome opso-myoclonique de l’efant. Nouvelle observation. Revue de la literature (110 cas). Pediatrie. 1985;6:441-9.

  5. Dávila-Gutiérrez G. Encefalopatía mioclonica infantil. Experiencia de l5 años en el diagnóstico y tratamiento. Tesis de Pediatría. Facultad de Medicina, División de Estudios Superiores de la UNAM. México, DF 1984.

  6. Pranzatelli MR. The neurobiology of the opsoclonus- myoclonus syndrome. Clinical neuropharmacology. Clin Neuropharmacol. 1992;l5:186-228.

  7. Dávila-Gutiérrez G, García J. Experiencia de 27 años en el diagnóstico y tratamiento de la encefalopatía mioclónica infantil. Rev Mex Neuroci. 2009;10(2):151.

  8. Kuban KC, EphrosMA, Freeman RL, Lafell LB, Bresan MJ. Opsoclonus myoclonus sindrome caused by Coxsackie B3 infection. Ann Neurol. 1983;13:69-71.

  9. Ramos S, Temudo T. Síndrome de opsoclono-mioclono: ¿hasta cuándo seguir investigando? Rev Neurol. 2002;35(4):322-5. 10. Uroz TJ, Hernández C, Beltra R, Vidal R, Melwani M. Síndrome opsoclono-mioclono y neuroblastoma. Rev Oncol. 2004;6(3):170-2.

  10. Ziegelbaum MM, Kay R, Rother D,Lorig R. The association of neuroblastoma with myoclonic encephalopathy of infants:the use of magnetic resonance as an imaging modality. J Urol. 1988;139:81-2.

  11. Bukola BO, Shapiro S. Dancing eyes, dancing feet. Opsoclonus- myoclonus in an l8 month old child with neuroblastoma. Pediatr Emerg Care. 2007;23:885-8.

  12. Aguilera S, Botella M, Salado C, Bosque A,Ocio I, Montiano J. Síndrome opso-mioclono atáxico paraneoplásico. An Sist Sanit Navar. 2009;32:91-5.

  13. Dávila GG. Síndrome de Elejalde en: Memorias de la Reunión Anual de la Academia Mexicana de Neurología. Chihuahua, México: 1988. p. 22.

  14. Nickerson BG, Hutter J. Opsomyoclonus and neuroblastoma. Response to ACTH. Clin Pediatr. 1979;l8.446-8.

  15. Barragán PE, Velarde E, Garza M, Hernández A. Causas no oncológicas del síndrome de Kinsbourne. Bol Med Hosp Infant Mex. 2005;62:189-94.

  16. Hunter S, Kooistra C. Neuropathologic findings in idiopathic opsoclonus and myoclonus. J Clin Neuro-ophthalmol. 1986;6:236-41.

  17. Yakovlev PI. A case of myoclonus epilepsy with atrophy of brain-stem and Hallervorden Spatz type of pathologic change in the pallidum, substantia nigra and dentate nucleus. Trans Am Neurol Assoc. 1942;68:95-100.

  18. Matsumma K, Sonoh M, Tomaoka A,Sakuta M. Syndrome of opsoclonus-myoclonus in hyperosmolar non ketotic coma. Ann Neurol. 1985;18:623-4.

  19. Hoyt CM. Neonatal opsoclonus. J Pediatr Ophthalmol. 1977;14:274-7.

  20. Wilken B, Baumann M, Bien C,Hero b, Rostasy K, Henefeld F. Chronic relapsing opsoclonus myoclonus syndrome: Combination of cyclophosphamide and dexamethasone pulses. J Eur Pediatrics Neurol. 2008;12:51-5.

  21. Hayward K, Jeremy R, Jenkis S, Barkovich A,Gultekin S, Kramer J, Crittenden M, Matthay K. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus myoclonus ataxia syndrome: relationship to MRI findings and anti neuronal antibodies. J Pediatr. 2001;139:552-9.

  22. Kelalis P, King L, Belman B. Adrenal, sympathetic chain and retroperitoneal tumors. In: Belman B, King L, Stephen A. Kramer S, eds. Clinical Pediatric Urology. 3rd ed. Philadelphia: WB Saunders; 2001. p. 1383-95.

  23. Beneke R, von Zwei F. Ganglioneuroma. Beitr Pathol Anat. 1901;30:1-48.

  24. Busch E. On ganglioneuroblastoma sympathicum. Pathol Microbiol Scand. 1928;5:289-305.

  25. Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors. Cancer. 2001;92:2451-61.

  26. Peuchmaur M, D’Amore E, Joshi V, Hata J, Borghild R, Dehner LP, et al.Revision of the international neuroblastoma pathology classification. Confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma nodular. Cancer. 2003;98:2274-81.

  27. Shapiro B. Locating neuroblastoma in the opsoclonus-myoclono syndrome. J Nucl Biol Med. 1994;38:545-55.

  28. Aldrich PM, Shalaby-Rana E,Movassaghi N,Majd M. The role of 131 iodine metaiodobenzylguanidine scanning in the correlative imaging of patients with neuroblastoma. Pediatrics. 1996;97:246- 50.

  29. Stefanowicz J, Izycka-Swieszewska E, Drozynska E, Pienczk J, Polczynska K, Czauderna P. Neuroblastoma and opsoclonus- myoclonus-ataxia syndrome-clinical and pathological characteristics. Folia Neuropathol. 2008;46(3):176-85.

  30. Raffaghello L,Conte M, De Grandis E, Pistoia V. Immunological mechanisms in opsoclonus-myoclonus associated neuroblas toma. Eur J Paediatr Neurol. 2009;13:219-23.

  31. Martin A, Messineo A,Lionetti P,Volta U, Stanghellini V, Barbara G. A case of paraneoplastic inflammatory neuropathy of the gastrointestinal tract related to an underlying neuroblastoma: successful management with immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2008;46:457-60.

  32. Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr. 2007;166:359-63.

  33. Drukker CA,Heij H, Wijnaendts L, Verbeke J, Kaspers G. Paraneoplastic gastrointestinal anti Hu syndrome in neuroblastoma. Pediatr Blood Cancer. 2009;52:396-8.

  34. Artigas PE, Sánchez E, Marlon V, Dávila G. Tumores derivados de la cresta neural en pacientes con encefalopatía opsomioclónica (Síndrome de Kinsbourne). Experiencia de 20 años con niños mexicanos. Acta Pediatr Mex. 2006;27(4):245-6.

  35. Wheeler DS, Starr S. Case 2 presentation. Opsoclonusmyoclonus syndrome. Pediatr Rev. 1998;19:281-3.

  36. Phol KRE, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996;155:237-44.

  37. Pranzatelli RM, Tate E, Travelstead A, Longge D. Immunologic and clinical responses to Rituximab in a child with opsoclonusmyoclonus syndrome. Pediatrics. 2005;115:115-9.

  38. Yiu VWY, Kovithavongs T, Mc Gonigle L, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus myoclonus syndrome. Pediatr Neurol. 2001;24:72-4.

  39. Armstrong BM, Robertson L, Castle P. Delay, recurrent opsoclonus- myoclonus syndrome responding to plasmapheresis. Pediatr Neurol. 2005;33:365-7.

  40. Veneselli E, Conte M, Biancheri R, Acquaviva A, De Bernardi B. Effect of steroid and high dose immunoglobulin therapy opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol. 1998;30:15-7.

  41. Conolly AM, Pestronk A, Metha S, Prantazelli M, Noetzel M. Serum antibodies in childhood opsoclonus-myoclonus syndrome: an analisis of antigenic targets in neuronal tissues. J Pediatr. 1997;130:878-84.

  42. Fisher PG, Wechsler D, Singer H. Anti Hu antibody in neuroblastoma associated paraneoplastic syndrome. Pediatr Neurol. 1994;10:309-12

  43. Corapcioglu F, Mutlu H, Kara B, Inan N, Akansel G,Gürbüz Y. Response to rituximab and prednisolone for opsoclonusmyoclonus- ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol. 2008;25:756-61.

  44. Pranzatelli RM, Tate E, Travelstead A, Barbosa J, Bergamini A,Civitello L, et al. Rituximab (anti CD20) adjunctive therapy for opsoclonus- myoclonus syndrome. Pediatrics. 2006;28:585- 93.

  45. Pranzatelli RM, Tate E, Hoefgen E, Wan J, Colliver J. Therapeutic down-regulation of central and peripheral B-cell activating factor (BAFF) production in pediatric opsoclonus myoclonus syndrome. Cytokine. 2008;4:26- 32.

  46. Pranzatelli RM, Tate E, Travelstead L,Baumgarder A, Gorda V, Haltore N y cols. Insights on chronic-relapsing opsoclonusmyoclonus from pilot study of mycophenolate mofetil. J Child Neurol. 2009;24:316-21

  47. Chang HB, Koch T, Hopkins K, Malempati S. Neuroblastoma found in a 4 year old after rituximab therapy for opsoclonusmyoclonus. Pediatr Neurol. 2006;35:213-5.

  48. Pranzatelli RM, Tate E, Travelstead L, Crowley, Toennies B, Creer M. Neurometabolic effects of ACTH on free amino compounds in opsoclonus- myoclonus syndrome. Neuropediatrics. 2008;39:164-71.

  49. Bell J, Moran C, Blatt J. Reponse to rituximab in a child with neuroblastoma and opsoclonus- myoclonus. Pediatr Blood Cancer. 2008;50:370-1.

  50. Leen GW , Weemaes C, Verbeek M, Willemsen M, Rotteveel J. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus myoclonus. Pediatr Neurol. 2008;39: 213-7.




2020     |     www.medigraphic.com